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Typhoid fever is a major cause of morbidity, with 
an estimated global incidence of 21,650,974 new-
cases, and 216,510 deaths, as of 2000 (1). Caused 
by Salmonella enterica subspecies enterica serotype 
Typhi (S. Typhi) and Paratyphi, this waterborne 
and foodborne infection has an annual incidence 
approaching 1% in endemic areas (2-4). Histori-
cally, surveillance studies have reported peak inci-
dences among children aged 5-15 years. However, 
recent investigations in South Asia (4-6) and else-
where in the region (7,8) reported high rates of 
infection among young children, with young age 
identified as a risk factor for infection.This has led 
to a re-assessment of the burden and the need for 
effective vaccination strategies for young preschool 
children (9). A driving force for vaccination, apart 
from the burden of disease, is the mounting con-
cern over rising drug resistance (10).
Despite evidence of the high burden of typhoid fe-
ver by both S.  enterica serovar Typhi and Paratyphi 
throughout Asia and sub-Saharan Africa (1) and 
public demand in endemic countries (9), most de-
veloping countries do not have a vaccination pro-
gramme or policy. Several factors have contributed 
to this, including concerns over competing costs in 
developing countries (9).
In this issue of JHPN, Cook et al. ask three basic 
questions: (a) would a programme providing vac-
cine free of charge to users pass a social benefits 
test; (b) would that vaccine be a wise use of public-
sector resources; (c) if the vaccine satisfies question 
1 and 2, how can it be financed? (11). The latter is 
perhaps the most relevant to developing countries 
and is often the most challenging from a practical 
standpoint.
The authors then provide an economic analysis, 
highlighting the benefit of public expenditure for 
typhoid Vi polysaccharide vaccine using three met-
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rics of economic benefit: private and public cost-of-
illness (COI) avoided; avoided COI plus mortality 
risk-reduction benefits; and willingness-to-pay. This 
represents a more rigorous set of measurements 
than many conventional analyses of health eco-
nomics and was conducted on sites that currently 
host ongoing studies on typhoid fever. 
In addressing these three questions, the authors ex-
amined three potential vaccination scenarios: vac-
cination of all enrolled school children; vaccina-
tion of all children; and vaccination of adults and 
children. Addressing the first question, ‘would 
a vaccine programme that dispensed Vi vaccine 
free of charge pass a social cost-beneift test?’, they 
found that, restricting economic benefits to ‘treat-
ment costs avoided’, none of the vaccination strate-
gies would pass a social cost-benefit test. They point 
out, however, that the definition of treatment cost 
avoided is not only restrictive but likely underesti-
mates true costs that are important to people, such 
as pain and suffering. Importantly, benefits, such as 
indirect protection to non-vaccinated persons, are 
not factored into the social cost-benefit analysis but 
are no less important. 
However, when the authors used the common 
standard of cost per disability-adjusted life-year 
(DALY), they found that all the three strategies 
would be ‘very cost-effective’. Importantly, at a cost 
of just over US$ 1, they found that a typhoid-vacci-
nation programme would absorb one-sixth of pub-
lic-sector health spending in India (on a per-capita 
basis). This addressed the second question, ‘would 
such a programme be a wise use of public-sector 
resources?’, and that appears to be yes, it would. 
Addressing the third question, the authors provide 
a more qualified answer. Drawing upon figures of 
public and private spending for health services in 
India, they argue that there is scope for the Gov-
ernment of India to share the cost of vaccination 
with a growing wealthier class. At a modest cost of 
US$ 1.07 per vaccinated person, any of the three 
vaccination strategies would then absorb nearly a 
sixth of current per-capita public-health spending. 
In short, at a modest cost, the wealthier households 
could subsidize a portion of the cost for lower-in-
come households.
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mand for typhoid vaccine, the Indian Government 
could employ user-fees to create a sustainable vac-
cination programme. Importantly, were adults to 
pay a higher user-fee, this could subsidize vaccines 
for children, who bear a higher burden of typhoid, 
which, in turn, would further reduce the number 
of new incident cases than would a flat user-fee and 
that this would still remain financially sustainable. 
This is a timely paper, given the very recent evi-
dence documenting the benefit of polysaccharide 
Vi vaccine in children aged two years or older in 
Kolkata, India, showing an 80% protective effec-
tiveness in children aged 2-5 years, with a 44% in-
direct protective effect on non-vaccinated persons 
for an overall 57% protective effectiveness to the 
whole community (12). This vaccine trial, in which 
members of the current economic analysis took 
part, strongly substantiated the potential impact 
and value of routine typhoid fever vaccination in 
an endemic urban setting. 
In light of the growing spread of typhoid fever, par-
ticularly in urban centres throughout the develop-
ing world, but especially in Asia, and the spread of 
antimicrobial resistance among Salmonella species, 
with its attendant treatment failure and increase in 
cost of care, a vaccination programme for typhoid 
fever would seem to be an obvious choice. Faced 
too with the evidence of disproportionate burden 
of disease among children, including those aged 
less than five years, any vaccination programme 
must offer direct benefit and relief to young chil-
dren. A take-home message from this analysis is 
that the sustainability of such a programme may 
ultimately hinge less on economic or even clinical 
metrics than on the community-mindedness of 
those at risk, and the willingness of a few to make a 
small sacrifice for the benefit of the whole.
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